citalopram has been researched along with Cerebral Ischemia in 24 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A secondary analysis of data from the multicentre randomised controlled trial The Efficacy of Citalopram Treatment in Acute Ischemic Stroke (TALOS)." | 9.69 | Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. ( Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023) |
| "This study aimed to investigate whether the routine administration of escitalopram for three months would improve the prognosis of patients with ischemic stroke and decrease the plasma copeptin level." | 9.34 | Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. ( Cao, JX; Chen, JC; Liu, L; Sun, YT; Wang, Y; Zeng, QH, 2020) |
| "We evaluated the effect of SSRI treatment on platelet aggregation in patients with ischaemic stroke and included patients from the randomized double-blind controlled study of citalopram in acute ischaemic stroke (TALOS)." | 9.30 | Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2019) |
| "TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke." | 9.20 | TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015) |
| "to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 7.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
| "The effects of citalopram, a serotonin (5-HT) reuptake inhibitor, on cerebral blood flow (CBF) and concentration of 5-HT and its metabolite were investigated in spontaneously hypertensives rats (SHR) subjected to forebrain ischemia." | 7.69 | Citalopram, a serotonin reuptake inhibitor, and brain ischemia in SHR. ( Fujishima, M; Ibayashi, S; Izumi, J; Nagao, T; Sadoshima, S, 1995) |
| "Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients." | 6.84 | Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. ( Abbaszade, Z; Ghazanfari Amlashi, S; Golzari, SEJ; Hashemilar, M; Nikanfar, M; Rikhtegar, R; Sadeghi Bazargani, H; Sadeghihokmabadi, E; Savadi Oskouie, D; Sharifipour, E, 2017) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 5.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| "A secondary analysis of data from the multicentre randomised controlled trial The Efficacy of Citalopram Treatment in Acute Ischemic Stroke (TALOS)." | 5.69 | Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. ( Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023) |
| "Citalopram treatment had no significant effect on infarct formation or edema 3 days after stroke; however, citalopram-treated mice had better functional recovery than saline-treated controls 3 and 14 days after stroke in the adhesive removal test." | 5.39 | Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. ( Espinera, AR; Gu, X; Ogle, ME; Wei, L, 2013) |
| "This study aimed to investigate whether the routine administration of escitalopram for three months would improve the prognosis of patients with ischemic stroke and decrease the plasma copeptin level." | 5.34 | Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction. ( Cao, JX; Chen, JC; Liu, L; Sun, YT; Wang, Y; Zeng, QH, 2020) |
| "We evaluated the effect of SSRI treatment on platelet aggregation in patients with ischaemic stroke and included patients from the randomized double-blind controlled study of citalopram in acute ischaemic stroke (TALOS)." | 5.30 | Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2019) |
| "TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke." | 5.20 | TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015) |
| "to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 3.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
| " The aim of this study was to investigate the effects of the SSRIs citalopram and fluoxetine, on the corticocerebral blood flow (cCBF) in rabbits with unilateral carotid occlusion induced cerebral ischemia." | 3.74 | Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. ( Csete, K; Papp, JG; Sas, K; Sztriha, L; Vécseil, L; Vezekényi, Z, 2007) |
| "The effects of citalopram, a serotonin (5-HT) reuptake inhibitor, on cerebral blood flow (CBF) and concentration of 5-HT and its metabolite were investigated in spontaneously hypertensives rats (SHR) subjected to forebrain ischemia." | 3.69 | Citalopram, a serotonin reuptake inhibitor, and brain ischemia in SHR. ( Fujishima, M; Ibayashi, S; Izumi, J; Nagao, T; Sadoshima, S, 1995) |
| "Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients." | 2.84 | Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. ( Abbaszade, Z; Ghazanfari Amlashi, S; Golzari, SEJ; Hashemilar, M; Nikanfar, M; Rikhtegar, R; Sadeghi Bazargani, H; Sadeghihokmabadi, E; Savadi Oskouie, D; Sharifipour, E, 2017) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 1.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| "Citalopram treatment had no significant effect on infarct formation or edema 3 days after stroke; however, citalopram-treated mice had better functional recovery than saline-treated controls 3 and 14 days after stroke in the adhesive removal test." | 1.39 | Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. ( Espinera, AR; Gu, X; Ogle, ME; Wei, L, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Bennet, L | 1 |
| McGregor, AL | 1 |
| Vestergaard, SB | 1 |
| Damsbo, AG | 2 |
| Blauenfeldt, RA | 1 |
| Johnsen, SP | 4 |
| Andersen, G | 4 |
| Mortensen, JK | 4 |
| Kraglund, KL | 3 |
| Grove, EL | 3 |
| Cao, JX | 1 |
| Liu, L | 1 |
| Sun, YT | 1 |
| Zeng, QH | 1 |
| Wang, Y | 1 |
| Chen, JC | 1 |
| Savadi Oskouie, D | 1 |
| Sharifipour, E | 1 |
| Sadeghi Bazargani, H | 1 |
| Hashemilar, M | 1 |
| Nikanfar, M | 1 |
| Ghazanfari Amlashi, S | 1 |
| Abbaszade, Z | 1 |
| Sadeghihokmabadi, E | 1 |
| Rikhtegar, R | 1 |
| Golzari, SEJ | 1 |
| Gupta, S | 1 |
| Upadhayay, D | 1 |
| Sharma, U | 1 |
| Jagannathan, NR | 1 |
| Gupta, YK | 1 |
| Modrau, B | 1 |
| Simonsen, SA | 1 |
| Iversen, HK | 1 |
| Madsen, M | 1 |
| Espinera, AR | 1 |
| Ogle, ME | 1 |
| Gu, X | 1 |
| Wei, L | 1 |
| Dhami, KS | 1 |
| Churchward, MA | 1 |
| Baker, GB | 1 |
| Todd, KG | 1 |
| Zhitkova, JV | 1 |
| Gao, J | 1 |
| Lin, M | 1 |
| Zhao, J | 1 |
| Bi, S | 1 |
| Ni, Z | 1 |
| Shang, X | 1 |
| Vetrugno, R | 1 |
| Vella, A | 1 |
| Mascalchi, M | 1 |
| Alessandria, M | 1 |
| D'Angelo, R | 1 |
| Gallassi, R | 1 |
| Della Nave, R | 1 |
| Ginestroni, A | 1 |
| Antelmi, E | 1 |
| Montagna, P | 1 |
| Bella, R | 1 |
| Pennisi, G | 1 |
| Cantone, M | 1 |
| Palermo, F | 1 |
| Pennisi, M | 1 |
| Lanza, G | 1 |
| Zappia, M | 1 |
| Paolucci, S | 1 |
| Sas, K | 2 |
| Lee, CH | 1 |
| Park, JH | 1 |
| Yoo, KY | 1 |
| Choi, JH | 1 |
| Hwang, IK | 1 |
| Ryu, PD | 1 |
| Kim, DH | 1 |
| Kwon, YG | 1 |
| Kim, YM | 1 |
| Won, MH | 1 |
| Aggarwal, A | 1 |
| Kumar, R | 1 |
| Sharma, R | 1 |
| Sharma, DD | 1 |
| Wang, SH | 2 |
| Zhang, ZJ | 2 |
| Guo, YJ | 2 |
| Teng, GJ | 2 |
| Chen, BA | 2 |
| Csete, K | 1 |
| Vezekényi, Z | 1 |
| Sztriha, L | 1 |
| Vécseil, L | 1 |
| Papp, JG | 1 |
| Nagao, T | 1 |
| Ibayashi, S | 1 |
| Sadoshima, S | 1 |
| Izumi, J | 2 |
| Fujishima, M | 1 |
| Nakata, N | 1 |
| Suda, H | 1 |
| Tanaka, Y | 1 |
| Ikeda, Y | 1 |
| Kato, H | 1 |
| Itoyama, Y | 1 |
| Kogure, K | 1 |
| Kaschka, WP | 1 |
| Meyer, A | 1 |
| Schier, KR | 1 |
| Fröscher, W | 1 |
| Gekht, AB | 1 |
| Bogolepova, AN | 1 |
| Sorokina, IB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis[NCT05480878] | Phase 3 | 90 participants (Actual) | Interventional | 2022-12-02 | Completed | ||
| The Efficacy of Citalopram Treatment in Acute Stroke[NCT01937182] | Phase 2 | 642 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for citalopram and Cerebral Ischemia
| Article | Year |
|---|---|
Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark.
Topics: Aged; Brain Ischemia; Citalopram; Denmark; Depression; Exercise; Female; Humans; Ischemic Stroke; Ma | 2023 |
Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Double-Blind Method; Female; Humans; Male; Midd | 2019 |
Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction.
Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Citalopram; Humans; Stroke; United States | 2020 |
Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Double-Blind Method; Female; Follow-Up S | 2017 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke.
Topics: Brain Ischemia; Citalopram; Double-Blind Method; Follow-Up Studies; Humans; Mental Status Schedule; | 2015 |
Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopram; Depressive Disorder; Fem | 2017 |
[Post-stroke depression: an experience in using cipramil].
Topics: Antidepressive Agents, Tricyclic; Brain Ischemia; Citalopram; Cognition Disorders; Depressive Disord | 2002 |
16 other studies available for citalopram and Cerebral Ischemia
| Article | Year |
|---|---|
Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice.
Topics: Animals; Brain Ischemia; Citalopram; Disease Models, Animal; Encephalitis; Ischemic Stroke; Mice; Ne | 2022 |
Citalopram attenuated neurobehavioral, biochemical, and metabolic alterations in transient middle cerebral artery occlusion model of stroke in male Wistar rats.
Topics: Animals; Brain; Brain Ischemia; Citalopram; Glutathione; Infarction, Middle Cerebral Artery; Male; M | 2018 |
Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice.
Topics: Animals; Brain Ischemia; Citalopram; Doublecortin Protein; Male; Mice; Mice, Inbred C57BL; Nerve Reg | 2013 |
Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult.
Topics: Animals; Brain Ischemia; Cell Hypoxia; Cell Survival; Cells, Cultured; Cerebral Cortex; Citalopram; | 2013 |
[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Citalopram; Cogniti | 2015 |
Peduncular hallucinosis: a polysomnographic and spect study of a patient and efficacy of serotonergic therapy.
Topics: Aged; Awareness; Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Internal; Citalopram; Dila | 2009 |
Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease.
Topics: Activities of Daily Living; Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopr | 2010 |
Potential role of glutamate neurotransmission in the pathogenesis of ischemic brain damage and of depression. Effects of L-kynurenine on the survival of the hippocampal neurons and on the corticocerebral blood flow in ischemic animal models.
Topics: Animals; Brain Ischemia; Cell Survival; Cerebrovascular Circulation; Chromatography, High Pressure L | 2010 |
Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress.
Topics: Analysis of Variance; Animals; Blotting, Western; Brain Ischemia; Brain-Derived Neurotrophic Factor; | 2011 |
Escitalopram and ischemic stroke: causal or chance association?
Topics: Adult; Antidepressive Agents; Brain Ischemia; Citalopram; Depressive Disorder; Humans; Male; Stroke | 2011 |
[Establishment of rat model of post-stroke depression and the effects of citalopram on behavior thereof].
Topics: Animals; Behavior, Animal; Brain Ischemia; Citalopram; Depressive Disorder; Disease Models, Animal; | 2007 |
Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.
Topics: Animals; Antidepressive Agents, Second-Generation; Blood Pressure; Brain Ischemia; Carotid Arteries; | 2007 |
Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress.
Topics: Adaptation, Physiological; Adaptation, Psychological; Animals; Antidepressive Agents, Second-Generat | 2008 |
Citalopram, a serotonin reuptake inhibitor, and brain ischemia in SHR.
Topics: Animals; Blood Pressure; Body Temperature; Brain Chemistry; Brain Ischemia; Cerebrovascular Circulat | 1995 |
Role of hippocampal serotonergic neurons in ischemic neuronal death.
Topics: 5,7-Dihydroxytryptamine; Animals; Brain Ischemia; Buspirone; Carotid Arteries; Cell Death; Citalopra | 1997 |
Treatment of pathological crying with citalopram.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopram; Crying; Female; Humans; | 2001 |